Vnitr Lek 2008, 54(7-8):745-750

Coagulopathy and differentiation syndrome: the main complications of the initial treatment of acute promyelocytic leukemia

Z. Kořístek1,*, P. Žák2
1 Interní hematoonkologická klinika Lékařské fakulty MU a FN Brno, pracoviště Bohunice, přednosta prof. MUDr. Jiří Vorlíček, CSc.
2 Oddělení klinické hematologie II. interní kliniky Lékařské fakulty UK a FN Hradec Králové, přednosta prof. MUDr. Jaroslav Malý, CSc.

Two main causes of early mortality of acute promyelocytic leukemia (APL) are rewieved, unique type of coagulopathy typical for APL and differentiation syndrome sometimes complicating treatment of APL with all-trans retinoic acid (ATRA) or arsenic trioxide (ATO). The information covers analysis of the patophysiologies of both conditions and also recommendations considering treatments and preventive measures.

Keywords: acute promyelocytic leukemia; differentiation syndrome; RAS; ATRA syndrome; ATO syndrome; coagulopathy; annexin II; hyperfibrinolysis

Received: June 9, 2008; Published: July 1, 2008  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Kořístek Z, Žák P. Coagulopathy and differentiation syndrome: the main complications of the initial treatment of acute promyelocytic leukemia. Vnitr Lek. 2008;54(7-8):745-750.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Castaigne S, Chomienne C, Daniel MT et al. All-trans retinoic acid as a differentiation therapy of acute promyelocytic leukemia. I. Clinical Results. Blood 1990; 76: 1704-1709. Go to original source...
    2. Frankel SR, Eardley A, Lauwers G et al. The "retinoic acid syndrome" in acute promyelocytic leukemia. Ann Intern Med 1992; 117: 292-296. Go to original source... Go to PubMed...
    3. Frankel SR, Eardley A, Heller G et al. All-trans retinoic acid for acute promyelocytic leukemia. Results of the New York study. Ann Intern Med 1994; 120: 278-286. Go to original source... Go to PubMed...
    4. Fenaux P, Le Deley MC, Castaigne S et al. Effect of all transretinoic acid in newly diagnosed acute promyelocytic leukemia. Results of a multicenter randomized trial. European APL 91 Group. Blood 1993; 82: 3241-3249. Go to original source...
    5. Vahdat L, Maslak P, Miller WH et al. Early mortality and the retinoic acid syndrome in acute promyelocytic leukemia: impact of leukocytosis, low-dose chemotherapy, PML/RAR-α isoform, and CD13 expression in patients treated with all-trans retinoic acid. Blood 1994; 84: 3843-3849. Go to original source...
    6. De Botton S, Dombret H, Sanz M et al. Incidence, clinical features, and outcome of all trans-retinoic acid syndrome in 413 cases of newly diagnosed acute promyelocytic leukemia. Blood 1998; 92: 2712-2718. Go to original source...
    7. Tallman MS, Andersen JW, Schiffer CA et al. Clinical description of 44 patients with acute promyelocytic leukemia who developed the retinoid acid syndrome. Blood 2000; 95: 90-95.
    8. Matikainen S, Tapiovaara H, Vaheri A et al. Activation of interleukin-1 beta gene expression during retinoic acid-induced granulocytic differentiation of promyeloid leukemia cells. Cell Growth Differ 1994; 5: 975-982.
    9. Di Noto R, Schiavone EM, Ferrara F et al. All-trans retinoic acid promotes a differential regulation of adhesion molecules on acute myeloid leukemia blast cells. Br J Haematol 1994; 88: 247-255. Go to original source... Go to PubMed...
    10. Cavenagh JD, Gordon-Smith EC, Gibson FM et al. Acute myeloid leukemia blast cells bind to human endothelium in vitro utilizing E-selectin and vascular cell adhesion molecule-1 (VCAM-1). Br J Haematol 1993; 85: 285-291. Go to original source... Go to PubMed...
    11. Stucki A, Rivier AS, Gikic M et al. Endothelial cell activation by myeloblasts: molecular mechanisms of leukostasis and leukemic cell dissemination. Blood 2001; 97: 2121-2129. Go to original source... Go to PubMed...
    12. Steeber DA, Tang ML, Green NE et al. Leukocyte entry into sites of inflammation requires overlapping interactions between the L-selectin and ICAM-1 pathways. J Immunol 1999; 163: 2176-2186. Go to original source...
    13. Rodriguez-Cimadevilla JC, Beauchemin V, Villeneuve L et al. Coordinate secretion of interleukin-1 beta and granulocyte-macrophage colony-stimulating factor by the blast cells of acute myeloblastic leukemia: role of interleukin-1 as an endogenous inducer. Blood 1990; 76: 1481-1489. Go to original source...
    14. Oster W, Cicco NA, Klein H et al. Participation of the cytokines interleukin 6, tumor necrosis factor-alpha, and interleukin 1-beta secreted by acute myelogenous leukemia blasts in autocrine and paracrine leukemia growth control. J Clin Invest 1989; 84: 451-457. Go to original source... Go to PubMed...
    15. Delwel R, van Buitenen C, Salem M et al. Interleukin-1 stimulates proliferation of acute myeloblastic leukemia cells by induction of granulocyte-macrophage colony-stimulating factor release. Blood 1989; 74: 586-593. Go to original source...
    16. Sanz MA, Martín G, González M et al. Risk-adapted treatment of acute promyelocytic leukemia with all-trans-retinoic acid and anthracycline monochemotherapy: a multicenter study by the PETHEMA group. Blood 2004; 103: 1237-1243. Go to original source... Go to PubMed...
    17. Didisheim P, Trombold JS, Vandervoort LE et al. Acute promyelocytic leukemia with fibrinogen and factor V deficiencies. Blood 1964; 23: 717-728. Go to original source...
    18. Drapkin RL, Gee TS, Dowling MD et al. Prophylactic heparin therapy in acute promyelocytic leukemia. Cancer 1978; 41: 2484-2490. Go to original source...
    19. Cordonnier C, Vernant JP, Brun B et al. Acute promyelocytic leukemia in 57 previously untreated patients. Cancer 1985; 55: 18-25. Go to original source...
    20. Rodeghiero F, Avvisati G, Castaman G et al. Early deaths and anti-hemorrhagic treatments in acute promyelocytic leukemia. A GIMEMA retrospective study in 268 consecutive patients. Blood 1990; 75: 2112-2117. Go to original source...
    21. Goldberg MA, Ginsburg D, Mayer RJ et al. Is heparin administration necessary during induction chemotherapy for patients with acute promyelocytic leukemia? Blood 1987; 69: 187-191. Go to original source...
    22. Keane TJ, Gorman AM, O'Connell LG et al. Epsilon-amino-caproic acid in the management of acute promyelocytic leukaemia. Acta Haematol 1976; 56: 202-204. Go to original source... Go to PubMed...
    23. Avvisati G, ten Cate JW, Büller HR et al. Tranexamic acid for control of haemorrhage in acute promyelocytic leukaemia. Lancet 1989; 2: 122-124. Go to original source... Go to PubMed...
    24. Hoyle CF, Swirsky DM, Freedman L et al. Beneficial effect of heparin in the management of patients with APL. Br J Haematol 1988; 68: 283-289. Go to original source... Go to PubMed...
    25. Gralnick HR, Abrell E. Studies of the procoagulant and fibrinolytic activity of promyelocytes in acute promyelocytic leukemia. Br J Haematol 1973; 24: 89-99. Go to original source... Go to PubMed...
    26. Bauer KA, Rosenberg RD. Thrombin generation in acute promyelocytic leukemia. Blood 1984; 64: 791-796. Go to original source...
    27. Bennett M, Parker AC, Ludlam CA. Platelet and fibrinogen survival in acute promyelocytic leukemia. Brit Med J 1976; 2: 565. Go to original source... Go to PubMed...
    28. Avvisati G, ten Cate JW, Sturk A et al. Acquired alpha-2-antiplasmin deficiency in acute promyelocytic leukaemia. Br J Haematol 1988; 70: 43-48. Go to original source... Go to PubMed...
    29. Sakata Y, Murakami T, Noro A et al. The specific activity of plasminogen activator inhibitor-1 in disseminated intravascular coagulation with acute promyelocytic leukemia. Blood 1991; 77: 1949-1957. Go to original source...
    30. Sterrenberg L, Haak HL, Brommer EJ et al. Evidence of fibrinogen breakdown by leukocyte enzymes in a patient with acute promyelocytic leukemia. Haemostasis 1985; 15: 126-133. Go to original source... Go to PubMed...
    31. Imaoka S, Ueda T, Shibata H et al. Fibrinolysis in patients with acute promyelocytic leukemia and disseminated intravascular coagulation during heparin therapy. Cancer 1986; 58: 1736-1738. Go to original source...
    32. Menell JS, Cesarman GM, Jacovina AT et al. Annexin II and bleeding in acute promyelocytic leukemia. N Engl J Med 1999; 340: 994-1004. Go to original source... Go to PubMed...
    33. Brower MS, Harpel PC. Proteolytic cleavage and inactivation of α2-plasmin inhibitor and C1 inactivator by human polymorphonuclear leukocyte elastase. J Biol Chem 1982; 257: 9849-9854. Go to original source...
    34. Kawai Y, Watanabe K, Kizaki M et al. Rapid improvement of coagulopathy by all-trans retinoic acid in acute promyelocytic leukemia. Am J Hematol 1994; 46: 184-188. Go to original source... Go to PubMed...
    35. Zokas L, Glenney JR Jr. The calpactin light chain is tightly linked to the cytoskeletal form of calpactin I: studies using monoclonal antibodies to calpactin subunits. J Cell Biol 1987; 105: 2111-2121. Go to original source... Go to PubMed...
    36. Levin MD, Betjes MG, V d Kwast TH et al. Acute renal cortex necrosis caused by arterial thrombosis during treatment for acute promyelocytic leukemia. Haematologica 2003; 88: ECR21.
    37. Hashimoto S, Koike T, Tatewaki W et al. Fatal thromboembolism in acute promyelocytic leukemia during all-trans retinoic acid therapy combined with antifibrinolytic therapy for prophylaxis of hemorrhage. Leukemia 1994; 8: 1113-1115. Go to PubMed...
    38. Tsukada N, Wada K, Aoki S et al. Induction therapy with all-trans retinoic acid for acute promyelocytic leukemia: a clinical study of 10 cases, including a fatal case with thromboembolism. Intern Med 1996; 35: 10-14. Go to original source... Go to PubMed...
    39. Avvisati G, Lo Coco F, Diverio D et al. AIDA (all-trans retinoic acid + idarubicin) in newly diagnosed acute promyelocytic leukemia: A Gruppo Italiano Malattie Ematologiche dell'Adulto (GIMEMA) pilot study. Blood 1996; 88: 1390-1398. Go to original source...
    40. Sanz MA, Tallman MS, Lo-Coco F. Tricks of the trade for the appropriate management of newly diagnosed acute promyelocytic leukemia. Blood 2005; 105: 3019-3025. Go to original source... Go to PubMed...
    41. Sanz MA, Lo Coco F. Standard practice and contoversial issues in front-line therapy of acute promyelocytic leukemia. Haematologica 2005; 90: 840-845. Go to PubMed...
    42. Adès L, Chevret S, Raffoux E et al. Is cytarabine useful in the treatment of acute promyelocytic leukemia? Results of a randomized trial from the European Acute Promyelocytic Leukemia Group. J Clin Oncol 2006; 24: 5703-5710. Go to original source... Go to PubMed...
    43. Barbui T, Finazzi G, Falanga A. The impact of all-trans-retinoic acid on the coagulopathy of acute promyelocytic leukemia. Blood 1998; 91: 3093-3102. Go to original source...

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.